Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 5Gastrointestinal 2Breast 2Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 402Triple Negative Breast Neoplasms 64Neoplasm Metastasis 50Neoplasms 19Breast Neoplasms, Male 14Colorectal Neoplasms 13Brain Neoplasms 13Stomach Neoplasms 11Pancreatic Neoplasms 11Colonic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Inflammatory Breast Neoplasms 6HER2-positive Breast Cancer 6Squamous Cell Carcinoma of Head and Neck 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Advanced Breast Cancer 5Rectal Neoplasms 4HER2 Positive Metastatic Breast Cancer 4Breast Cancer Metastatic 4Sarcoma 3Prostatic Neoplasms 3Meningeal Neoplasms 3Lymphoma, Non-Hodgkin 3Gallbladder Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Unknown Primary 2

Interventions

pembrolizumab 19Magnetic Resonance Spectroscopy 17Docetaxel 13Specimen Handling 12Radiotherapy 11Surveys and Questionnaires 10Cyclophosphamide 10Blood Specimen Collection 9Radiosurgery 8Paclitaxel 8Gemcitabine 8Drug Therapy 8sargramostim 7Trastuzumab 7Nivolumab 7Carboplatin 7Injections 6Early Intervention, Educational 6Taxes 5Psychiatric Rehabilitation 5Methods 5Interviews as Topic 5Educational Status 5spartalizumab 4motexafin gadolinium 4aldesleukin 4X-Rays 4Therapeutics 4Standard of Care 4Spinal Puncture 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × Capecitabine × Breast × Clear all
NCT02955940 2025-12-17

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Incyte Corporation

Phase 2 Active not recruiting
10 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡